Scholarlink

<p>The escalating crisis of antimicrobial resistance (AMR) necessitates the urgent development of alternatives to traditional antibiotics. Bacteriophage (phage) therapy, which utilizes viruses that specifically infect and lyse bacteria, has re-emerged as a promising therapeutic strategy. This review comprehensively examines the current landscape, beginning with the modern, genome-based classification of phages and detailing their key therapeutic advantages, including high specificity, self-amplification, and biofilm-penetrating capability. We explore advanced biotechnological applications such as genetic engineering of phages, the use of phage-derived proteins, and synergistic phage-antibiotic combinations (PAS). The translational workflow from phage sourcing and biobanking to characterization, formulation, and clinical delivery is critically analyzed, alongside major therapeutic areas like chronic wounds and pulmonary infections. Despite promising clinical evidence from compassionate use and trials, significant scientific, regulatory, and commercial hurdles remain. The integration of synthetic biology and artificial intelligence is poised to overcome these challenges, steering phage therapy toward becoming a precise and adaptable component of the modern antimicrobial arsenal.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Phage as a prospective arsenal against superbugs

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年8月4日

查看全文
  • Lejia Zhao,
  • Yirui Wan,
  • Sharon Shui Yee Leung,
  • Xuemei Yang,
  • Ping Zeng

摘要

The escalating crisis of antimicrobial resistance (AMR) necessitates the urgent development of alternatives to traditional antibiotics. Bacteriophage (phage) therapy, which utilizes viruses that specifically infect and lyse bacteria, has re-emerged as a promising therapeutic strategy. This review comprehensively examines the current landscape, beginning with the modern, genome-based classification of phages and detailing their key therapeutic advantages, including high specificity, self-amplification, and biofilm-penetrating capability. We explore advanced biotechnological applications such as genetic engineering of phages, the use of phage-derived proteins, and synergistic phage-antibiotic combinations (PAS). The translational workflow from phage sourcing and biobanking to characterization, formulation, and clinical delivery is critically analyzed, alongside major therapeutic areas like chronic wounds and pulmonary infections. Despite promising clinical evidence from compassionate use and trials, significant scientific, regulatory, and commercial hurdles remain. The integration of synthetic biology and artificial intelligence is poised to overcome these challenges, steering phage therapy toward becoming a precise and adaptable component of the modern antimicrobial arsenal.